Brad Marion
Pulmonary Disease · Oklahoma City, OKNPI 1679644348
Payments from drug & device makers
Across 142 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$740
- GSK$339
- Takeda Pharmaceuticals U.S.A., Inc.$223
- Boehringer Ingelheim$177
- Sunovion Pharmaceuticals Inc.$161
- Baxter Healthcare$145
- plus $664 from 16 others
What the payments were for
- Food & beverage$2,39998%
- Education$482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $740 |
| GSK | 28 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $223 |
| Boehringer Ingelheim | 10 | $177 |
| Sunovion Pharmaceuticals Inc. | 15 | $161 |
| Baxter Healthcare | 8 | $145 |
| Actelion Pharmaceuticals US, Inc. | 8 | $135 |
| Novartis | 5 | $79 |
| Mylan Specialty L.p. | 4 | $62 |
| Grifols USA, LLC | 2 | $40 |
| Sanofi | 2 | $40 |
| Shire North American Group Inc | 2 | $38 |
| CSL Behring | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Inogen, Inc. | 4 | $35 |
| Insmed, Inc. | 2 | $32 |
| AbbVie | 1 | $31 |
| Optinose US, Inc. | 2 | $31 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Gilead | 1 | $18 |
| Amgen | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,448 in reported general payments places this provider in the 45th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$2.4M
- Jad KebbeOklahoma City$1.5M
- Karen AllenOklahoma City$202K
- Robert GordonOklahoma City$160K
- Nicholas ShelburneOklahoma City$102K
- Tony AbdoOklahoma City$91K
- Fawad ChaudryOklahoma City$80K
- Loan NguyenOklahoma City$76K
- Maroun TawkOklahoma City$62K
- Adam PrzebindaOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.